The positive correlations of apolipoprotein E with disease activity and related cytokines in systemic lupus erythematosus

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Song, Li jun ^a   Liu, Wei wei ^a   Fan, Yu chen ^a   Qiu, Feng ^a   Chen, Qi lin ^a   Li, Xing fu ^a   Ding, Feng ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anti inflammatory cytokine; Apolipoprotein E; SLEDAI; Systemic lupus erythematosus

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CYTOKINE; DNA; GLUCOCORTICOID; PREDNISONE;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; DNA; DOWN-REGULATION; FEMALE; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDNISONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84885716312     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-175     Document Type: Article

References (40)

1. Csiszar A, Nagy G, Gergely P, et al. Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000, 122:464-470. 10.1046/j.1365-2249.2000.01369.x, 1905797, 11122256.
2. Eilertsen GO, Nikolaisen C, Becker-Merok A, et al. Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus 2011, 20:607-613. 10.1177/0961203310392432, 21422077.
3. Perniok A, Wedekind F, Herrmann M, et al. High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 1998, 7:113-118. 10.1191/096120398678919804, 9541096.
4. Ahsan H, Ali A, Ali R. Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol 2003, 131:398-404. 10.1046/j.1365-2249.2003.02104.x, 1808645, 12605691.
5. Dean GS, Tyrrell-Price J, Crawley E, et al. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000, 59:243-251. 10.1136/ard.59.4.243, 1753117, 10733469.
6. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arterioscler 1988, 8:1-21.
7. Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 1986, 136:3716-3723.
8. Yin M, Zhang L, Sun XM, et al. Lack of apoE causes alteration of cytokines expression in young mice liver. Mol Biol Rep 2010, 37:2049-2054. 10.1007/s11033-009-9660-x, 19644765.
9. Baitsch D, Bock HH, Engel T, et al. Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol 2011, 31:1160-1168. 10.1161/ATVBAHA.111.222745, 3529398, 21350196.
10. Zhang H, Wu LM, Wu J. Cross-talk between apolipoprotein E and cytokines. Mediators Inflamm 2011, 2011:949072. 3136159, 21772670.
11. Zhang HL, Wu J, Zhu J. The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Dev Immunol 2010, 2010:186813. 2896842, 20613949.
12. Postigo J, Genre F, Iglesias M, et al. Exacerbation of type II collagen-induced arthritis in apolipoprotein E-deficient mice in association with the expansion of Th1 and Th17 cells. Arthritis Rheum 2011, 63:971-980. 10.1002/art.30220, 21225684.
13. Mosca M, Tani C, Carli L, et al. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011, 29:S126-S129.
14. Schacke H, Berger M, Rehwinkel H, et al. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007, 275:109-117. 10.1016/j.mce.2007.05.014, 17630119.
15. Song L, Qiu F, Fan Y, et al. Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol 2013, 33:111-117. 10.1007/s10875-012-9791-z, 22961070.
16. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
18. Kumar Y, Bhatia A, Minz RW. Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagn Pathol 2009, 4:1. 10.1186/1746-1596-4-1, 2628865, 19121207.
19. Elshourbagy NA, Liao WS, Mahley RW, et al. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci U S A 1985, 82:203-207. 10.1073/pnas.82.1.203, 397000, 3918303.
20. Basheeruddin K, Rechtoris C, Mazzone T. Transcriptional and post-transcriptional control of apolipoprotein E gene expression in differentiating human monocytes. J Biol Chem 1992, 267:1219-1224.
21. Blue ML, Williams DL, Zucker S, et al. Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proc Natl Acad Sci USA 1983, 80:283-287. 10.1073/pnas.80.1.283, 393357, 6572003.
22. Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 2004, 173:6366-6375.
23. Rana A, Minz RW, Aggarwal R, et al. Gene expression of cytokines (TNF-alpha, IFN-gamma), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 2012, 21:1105-1112. 10.1177/0961203312451200, 22759859.
24. Chun HY, Chung JW, Kim HA, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007, 27:461-466. 10.1007/s10875-007-9104-0, 17587156.
25. Tenger C, Zhou X. Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell. Immunol 2003, 109:392-397.
26. Liu P, Song J, Su H, et al. IL-10 gene polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis. PLoS One 2013, 8:e69547. 10.1371/journal.pone.0069547, 3720721, 23936042.
27. Qiu F, Song L, Ding F, et al. Expression level of the growth factor progranulin is related with development of systemic lupus erythematosus. Diagn Pathol 2013, 8:88. 10.1186/1746-1596-8-88, 3680007, 23702100.
28. Golding A, Hasni S, Illei G, et al. The percentage of Foxp3 Helios T regulatory cells positively correlates with disease activity in systemic lupus erythematosus. Arthritis Rheum In press.
29. Szodoray P, Nakken B, Barath S, et al. Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders. Hum Immunol In press.
30. Kil LP, Hendriks RW. Aberrant B cell selection and activation in systemic lupus erythematosus. Int Rev Immunol 2013, 32:445-470. 10.3109/08830185.2013.786712, 23768157.
31. Hawker G, Gabriel S, Bombardier C, et al. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993, 20:657-660.
32. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990, 33:634-643. 10.1002/art.1780330505, 2346519.
33. Adcock IM, Brown CR, Gelder CM, et al. Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol 1995, 268:C331-C338.
34. DeKruyff RH, Fang Y, Umetsu DT. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J Immunol 1998, 160:2231-2237.
35. Peng J, Liu C, Liu D, et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood 2003, 101:2721-2726. 10.1182/blood-2002-06-1666, 12446456.
36. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998, 94:557-572.
37. Minihane AM, Jofre-Monseny L, Olano-Martin E, et al. ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc Nutr Soc 2007, 66:183-197. 10.1017/S0029665107005435, 17466101.
38. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 2008, 52:131-145. 10.1002/mnfr.200700322, 18203129.
39. Pablos-Mendez A, Mayeux R, Ngai C, et al. Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly population. Arterioscler Thromb Vasc Biol 1997, 17:3534-3541. 10.1161/01.ATV.17.12.3534, 9437203.
40. Wang X, Sun J, Wang G, et al. Relationship between blood lipid level and apolipoprotein E gene polymorphism in offspring from longevity and non-longevity families. Zhonghua Yu Fang Yi Xue Za Zhi 2000, 34:159-161.